 GW Pharmaceuticals PLC NASDAQ:GWPH, the medicinal cannabis giant, has received European Commission EC approval for the treatment of seizures associated with tuberous sclerosis complex. The EC has approved the Type II variation application for GWs EPIDYOLEX cannabidiol as an adjunctive treatment of seizures for patients two years old or older. 